Based on the Company's Clinical Development Plan, Oncolytics is investigating potential partnerships for its phase 3 registration program in metastatic breast cancer (mBC), as well as collaborations with checkpoint inhibitors and immunomodulatory drugs that will help advance REOLYSIN® in the adjuvant setting.

Collaborating with Myeloma UK and Celgene

We are working with Celgene and Myeloma UK, a cancer charity focused on improving quality of life for myeloma patients, to launch an immunotherapy trial that aims to treat relapsing myeloma patients by influencing the immune system.

Clinical Trial: MUK eleven

MUK eleven is a first-of-its-kind immunotherapy trial that aims to modulate the immune system to target myeloma. The trial, run through the Myeloma UK Clinical Trial Network (CTN) in collaboration with charity Myeloma UK, the University of Leeds, Oncolytics and Celgene, launched in March 2017 and will recruit approximately 44 patients across up to eight CTN centres in the UK. MUK eleven will study REOLYSIN® (pelareorep) in combination with Celgene's Imnovid® (pomalidomide) or Revlimid® (lenalidomide) in patients whose myeloma is progressing while being treated with one of these IMiDs. In addition to assessing the safety and tolerability of these combinations, the trial will investigate whether the addition of REOLYSIN® extends disease control in this patient group.

Partnering with Adlai Nortye

We are working with Adlai Nortye, a biopharmaceutical company focused on discovering and developing important new treatments for cancer and metabolic diseases, to advance our phase 3 registration program in mBC and to leverage their distinct experience and expertise in drug development and commercialization in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. Under the terms of The Agreement, Adlai Nortye has exclusive development and commercialization rights to REOLYSIN® for all indications in these territories.